FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897060157> ?p ?o ?g. }

• W2897060157 abstract "ALZ-801, an oral pro-drug of tramiporsate, received Fast Track designation for development as a disease modifying treatment for AD. ALZ-801 provides consistent plasma levels of the active agent tramiprosate with improved PK and GI tolerability (Hey et al. 2018). Tramiprosate inhibits formation of toxic soluble amyloid oligomers (Kocis et al. 2017) and was evaluated in Mild to Moderate AD patients. In the North American Phase 3 trial, patients homozygous for apolipoprotein e4 allele (APOE4/4) showed meaningful benefits in Mild AD patients (Abushakra et al. 2016 & 2017). We analyzed individual responses and response rates on the clinical outcomes. The 78-week NA trial enrolled 1,053 AD patients (MMSE16-26) to either placebo, tramiprosate 100mg BID, or 150mg BID; including 148 APOE4/4 homozygotes. At 150mg BID, APOE 4/4 homozygous patients with Mild AD showed significant and/or meaningful benefits on ADAS-cog and CDR-SB (co-primary endpoints) and DAD (disability assessment). For APOE4/4 Mild subgroups, individual changes from baseline were plotted for placebo and high dose (waterfall analysis). Responders were defined by changes on ADAS-cog ≤0 and CDR-SB ≤0 (no worsening); and DAD worsening ≤4 points. Responder analyses were conducted using Fisher's exact test. The APOE4/4 Mild subgroups in the high dose and placebo arms included n=65 (MMSE ³20) and n=50 (MMSE ³22). In MMSE ³20 group, responder proportions were: ADAS-cog 57% vs. 21% (p= 0.011), CDR-SB 35% vs. 25% (NS), and DAD 46% vs 18% (p= 0.039). In MMSE ³22 group, they were: ADAS-cog 67% vs. 24% (p= 0.011), CDR-SB 44% vs. 29% (NS), and DAD 56% vs. 20% (p= 0.024). Safety in the APOE4/4 subgroup was favorable, and the most common dose-dependent TEAE were nausea, vomiting, and weight loss (Abushakra et al, 2017). The responder analyses show that tramiprosate/ALZ-801 provides significant and meaningful benefits in APOE4/4 patients with Mild or Early AD. At the 150mg BID dose, approximately 57-67% of patients remained cognitively stable, and 46-56% had minimal or no functional decline over 1.5 years. These results will inform cut-off points for responder analyses in confirmatory ALZ-801 efficacy trials in this genetically defined AD population with high amyloid burden." @default.
• W2897060157 created "2018-10-26" @default.
• W2897060157 creator A5021670944 @default.
• W2897060157 creator A5033585095 @default.
• W2897060157 creator A5090441997 @default.
• W2897060157 date "2018-07-01" @default.
• W2897060157 modified "2023-10-16" @default.
• W2897060157 title "P4‐197: CLINICAL BENEFITS OF ORAL TRAMIPROSATE IN APOE4/4 HOMOZYGOTES WITH MILD ALZHEIMER'S DISEASE: RESPONDER ANALYSES FROM THE PHASE 3 NORTH AMERICAN TRIAL" @default.
• W2897060157 doi "https://doi.org/10.1016/j.jalz.2018.07.018" @default.
• W2897060157 hasPublicationYear "2018" @default.
• W2897060157 type Work @default.
• W2897060157 sameAs 2897060157 @default.
• W2897060157 citedByCount "0" @default.
• W2897060157 crossrefType "journal-article" @default.
• W2897060157 hasAuthorship W2897060157A5021670944 @default.
• W2897060157 hasAuthorship W2897060157A5033585095 @default.
• W2897060157 hasAuthorship W2897060157A5090441997 @default.
• W2897060157 hasConcept C126322002 @default.
• W2897060157 hasConcept C142724271 @default.
• W2897060157 hasConcept C197934379 @default.
• W2897060157 hasConcept C203092338 @default.
• W2897060157 hasConcept C204787440 @default.
• W2897060157 hasConcept C27081682 @default.
• W2897060157 hasConcept C2778375690 @default.
• W2897060157 hasConcept C535046627 @default.
• W2897060157 hasConcept C71924100 @default.
• W2897060157 hasConcept C90924648 @default.
• W2897060157 hasConceptScore W2897060157C126322002 @default.
• W2897060157 hasConceptScore W2897060157C142724271 @default.
• W2897060157 hasConceptScore W2897060157C197934379 @default.
• W2897060157 hasConceptScore W2897060157C203092338 @default.
• W2897060157 hasConceptScore W2897060157C204787440 @default.
• W2897060157 hasConceptScore W2897060157C27081682 @default.
• W2897060157 hasConceptScore W2897060157C2778375690 @default.
• W2897060157 hasConceptScore W2897060157C535046627 @default.
• W2897060157 hasConceptScore W2897060157C71924100 @default.
• W2897060157 hasConceptScore W2897060157C90924648 @default.
• W2897060157 hasIssue "7S_Part_29" @default.
• W2897060157 hasLocation W28970601571 @default.
• W2897060157 hasOpenAccess W2897060157 @default.
• W2897060157 hasPrimaryLocation W28970601571 @default.
• W2897060157 hasRelatedWork W1990121386 @default.
• W2897060157 hasRelatedWork W202460821 @default.
• W2897060157 hasRelatedWork W2030348591 @default.
• W2897060157 hasRelatedWork W2126066542 @default.
• W2897060157 hasRelatedWork W2144323667 @default.
• W2897060157 hasRelatedWork W2792976719 @default.
• W2897060157 hasRelatedWork W2901706913 @default.
• W2897060157 hasRelatedWork W3200621203 @default.
• W2897060157 hasRelatedWork W3212096909 @default.
• W2897060157 hasRelatedWork W4251484736 @default.
• W2897060157 hasVolume "14" @default.
• W2897060157 isParatext "false" @default.
• W2897060157 isRetracted "false" @default.
• W2897060157 magId "2897060157" @default.
• W2897060157 workType "article" @default.